Cargando…

Systemic anti-CD20 (rituximab) as primary treatment for symptomatic primary uveal lymphoma

PURPOSE: Uveal lymphomas are indolent, frequently choroid-involving neoplasms that are mainly CD20-positive B-cell extranodal marginal zone lymphoma. Irreversible visual loss may occur from retinal detachment and/or glaucoma among untreated symptomatic patients, or from radiation-induced changes sec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiu Teo, Honeylen Maryl, Çiftçi, Süleyman, Elner, Victor Maurice, Demirci, Hakan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586989/ https://www.ncbi.nlm.nih.gov/pubmed/31249903 http://dx.doi.org/10.1016/j.ajoc.2019.100484

Ejemplares similares

Tissue-Based Microarray Expression of Genes Predictive of Metastasis in Uveal Melanoma and Differentially Expressed in Metastatic Uveal Melanoma
por: Demirci, Hakan, et al.
Publicado: (2013)

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
por: Teo, Honeylen Maryl, et al.
Publicado: (2021)

Multimodal Imaging and Clinicopathologic Correlation in Primary Uveal Lymphoma
por: Erickson, Brandon, et al.
Publicado: (2016)

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
por: Mishima, Y, et al.
Publicado: (2011)

The Role of Rituximab in Primary Central Nervous System Lymphoma
por: Bromberg, Jacoline E. C., et al.
Publicado: (2020)

Primary uveal lymphoma effectively managed with oral chlorambucil: a case report
por: Rospond-Kubiak, Iwona, et al.
Publicado: (2013)

Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa
por: Annibali, Ombretta, et al.
Publicado: (2015)

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
por: Van Dijck, Ruben, et al.
Publicado: (2021)

Symptomatic hypopituitarism revealing primary suprasellar lymphoma
por: Fadoukhair, Zouhour, et al.
Publicado: (2010)

Primary Hepatic Lymphoma Masquerading as Symptomatic Hypercalcemia
por: Ali, Abdulla M., et al.
Publicado: (2020)

Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells
por: Luo, Chengke, et al.
Publicado: (2016)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Primary CD20‐positive mediastinal diffuse large B‐cell lymphoma
por: Rajabto, Wulyo, et al.
Publicado: (2020)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Rituximab monotherapy become an optimal treatment for primary pulmonary malt lymphoma
por: Alvarez-Sánchez, A.I., et al.
Publicado: (2018)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine
por: Jo, Tatsuro, et al.
Publicado: (2012)

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
por: Song, Lina, et al.
Publicado: (2019)

5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
por: Tsutsumi, Yutaka, et al.
Publicado: (2016)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases
por: Peterlin, Pierre, et al.
Publicado: (2018)

CD20(+) cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: Case report and review of the literature
por: Tschetter, Amanda J., et al.
Publicado: (2020)

Case report of primary CD20 negative diffuse large B-cell lymphoma
por: Devi, Kanti, et al.
Publicado: (2021)

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
por: Sekiguchi, Naohiro, et al.
Publicado: (2018)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

Rituximab Treatment of Primary Cutaneous Follicle Center Lymphoma: A Retrospective Review
por: Wang, Siru, et al.
Publicado: (2022)

SAT-185 Primary Adrenal Lymphoma Presenting with Symptomatic Hypercalcaemia
por: Forde, Hannah Elizabeth, et al.
Publicado: (2020)

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
por: Chu, Te-Wei, et al.
Publicado: (2015)

Cd20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab
por: Rasheed, Afshan Asghar, et al.
Publicado: (2018)

Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
por: Murakami, Mineko, et al.
Publicado: (2011)

Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab
por: Virmani, Pooja, et al.
Publicado: (2017)

Uveal melanoma: epidemiology, etiology, and treatment of primary disease
por: Krantz, Benjamin A, et al.
Publicado: (2017)

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma
por: Kim, Jee Hung, et al.
Publicado: (2018)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

An adolescent with uveal melanoma and BAP1 tumor predisposition syndrome
por: Young, Kelly Z., et al.
Publicado: (2020)

Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines
por: Kittler, Julia M., et al.
Publicado: (2019)

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2013)

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster
por: Li, Huafei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cenuis39vocov3ni3c77auea24